Ipsen adds a drug candidate to its oncology pipeline. In 2020, the French laboratory entered into a partnership with the University of Montreal (Canada) and IRICoR, an organization attached to the Quebec university and responsible for accelerating the discovery, development and marketing of new therapies.
And this R&D agreement is beginning to bear fruit, since Ipsen has exercised an option to recover the exclusive rights to a preclinical program in oncology. “We are determined to pursue the development of this experimental treatment while identifying its application to different types of tumors, both solid and hematological”, explained Christelle Huguet, Vice-President, Director of Research, External Innovation and Early Development at Ipsen.
VOS INDICES
source
The laboratory will make an initial payment to the Université de Montréal, the amount of which has not been specified. The university will also be eligible for additional payments, depending on the success of the product.
A second deal in the pipeline
Building on this success, Ipsen does not intend to stop there for this collaboration. The laboratory will extend this partnership to two early programs, still in oncology. Under the same mechanism, the university will be in charge of bringing the compounds to the drug candidate stage and Ipsen will then be able to exercise an option to recover the development and commercialization rights.
Oncology is a strong strategic focus for Ipsen, along with rare diseases and neurosciences. The French laboratory has added no less than twelve oncology assets to its pipeline over the past two years (excluding this last asset recovered in Quebec), out of the twenty integrated programs in total.
Selected for you
